See the DrugPatentWatch profile for januvia
Januvia was first approved by the U.S. Food and Drug Administration (FDA) in October 2006 [1].
What is Januvia used for?
Januvia (sitagliptin) is a prescription medication used to improve blood sugar control in adults with type 2 diabetes mellitus [2]. It belongs to a class of drugs called dipeptidyl peptidase-4 (DPP-4) inhibitors [2].
How does Januvia work?
Januvia works by increasing the levels of incretin hormones [3]. These hormones help to regulate blood sugar by increasing insulin release when blood sugar is high and decreasing the amount of sugar produced by the liver [3].
When does Januvia's patent expire?
The original patent for Januvia (sitagliptin) expired in November 2022 [4]. However, other patents related to its formulation and use may still be in effect [4]. Information on patent expiry can be found on DrugPatentWatch.com [4].
Are there generic versions of Januvia available?
Following the expiry of its primary patent, generic versions of sitagliptin have become available [5]. These generics offer a lower-cost alternative for managing type 2 diabetes [5].
What are the alternatives to Januvia?
Other medications for type 2 diabetes include metformin, sulfonylureas, thiazolidinediones, GLP-1 receptor agonists, and SGLT2 inhibitors [6]. The best treatment option depends on individual patient factors, including other medical conditions and treatment goals [6].